Revisiting Estrogen: Efficacy and Safety for Postmenopausal Bone Health
The rapid decline in endogenous estrogen production that occurs during menopause is associated with significant bone loss and increased risk for fragility fracture. While hormone therapy (HT) is an effective means to re-establish endogenous estrogen levels and reduce the risk of future fracture, its...
Main Authors: | Sandra M. Sacco, Wendy E. Ward |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Journal of Osteoporosis |
Online Access: | http://dx.doi.org/10.4061/2010/708931 |
Similar Items
-
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01) -
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
by: Kawate H, et al.
Published: (2011-06-01) -
The Ovariectomized Rat as a Model for Studying Alveolar Bone Loss in Postmenopausal Women
by: Bryan D. Johnston, et al.
Published: (2015-01-01) -
Mineral bone density association with estrogen alpha receptor gene (ESRa) polymorphisms at postmenopausal osteoporosis
by: M Y Krylov, et al.
Published: (2005-02-01) -
Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01)